Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2021
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.
Epistemonikos ID: ad130480afa1b4ea7f45939aee68bdb917b5b1fa
First added on: Feb 15, 2022